XORTX Therapeutics (XRTX) Operating Leases (2022 - 2023)
XORTX Therapeutics (XRTX) posted Operating Leases of $11510.0 for Q4 2023, little changed on a QoQ basis from $11483.7 in Q4 2022, and little changed year-over-year from $11483.7 in Q4 2022.
XORTX Therapeutics (XRTX) Operating Leases (2022 - 2023) Analysis & Trends
XORTX Therapeutics' Operating Leases history runs 2 years deep, the most recent figure standing at $11510.0 for Q4 2023.
- Quarterly Operating Leases changed 0.23% year-over-year to $11510.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $11510.0 (changed 0.23% YoY) and the FY2023 annual result came in at $11510.0, changed 0.01% from the prior year.
- Operating Leases was $11510.0 for Q4 2023 at XORTX Therapeutics, roughly flat from $11483.7 in the prior quarter.
- Across five years, Operating Leases topped out at $48001.6 in Q2 2022 and bottomed at $11483.7 in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | XORTX Therapeutics | 20.40 Mn | 20.40 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 11,510.00 |
| Dec 31, 2022 | 11,483.73 |
| Sep 30, 2022 | 29,609.44 |
| Jun 30, 2022 | 48,001.65 |